Navigation Links
Biosensors DES Demonstrates Equivalent Safety and Efficacy to Industry Leading DES in First 'Real World, All Comers' Clinical Study
Date:9/1/2008

MUNICH, Germany, September 1 /PRNewswire-FirstCall/ -- Biosensors International Group, Ltd ("Biosensors", "Company"), (Bloomberg: BIG:SP), (Singapore:B20) today announced that a next-generation drug-eluting stent, developed by Biosensors, has demonstrated equal safety and efficacy as compared to Johnson & Johnson's industry leading drug-eluting stent, CYPHER SELECT(TM) ("Cypher"), based upon nine-month clinical and angiographic follow-up data. The results of the landmark study were presented today at the 2008 European Society of Cardiology Congress and published concurrently on-line by the prestigious UK medical journal The Lancet.

LEADERS (Limus Eluted from A Durable versus ERodable Stent coating) is the first head-to-head randomized study between the two drug-eluting stent systems (DES) in a 'real world, all comers' population using clinical results as its primary endpoint.

This multi-centre European study randomized 1,707 patients eligible for percutaneous coronary intervention (PCI) for symptomatic coronary disease to receive either a Biosensors Biolimus-eluting DES with an abluminal biodegradable polymer coating, or a Cypher Sirolimus-eluting DES with a durable polymer. In total, 2,472 coronary lesions were treated. Inclusion criteria were broad, reflecting routine clinical practice, without limitations regarding type of coronary vessel, lesion length or number of treated lesions. Patient conditions known as "off-label indications", including acute coronary syndromes, saphenous vein grafts and previously treated lesions were also included in the trial.

The primary endpoint of the study was non-inferiority of the composite of cardiac death, myocardial infarction, and clinically-driven target vessel revascularization ("TVR") at nine months follow-up. In addition, 25 percent of all patients were randomly assigned to undergo angiographic follow-up at nine months. The principal endpoint of the pre-specified angiographic sub-group was in-s
'/>"/>

SOURCE Biosensors International Group, Ltd
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Virogenomics, Inc. Awarded $2 Million National Institute of Standards and Technology (NIST) Advanced Technology Program Grant to Develop Integrated Diagnostic Biosensors
2. Cytokine Demonstrates Oral Efficacy of Small-Molecule MIF Inhibitors
3. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
4. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
5. New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia
6. Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety
7. Lpath Demonstrates Preclinical Efficacy of Lpathomab(TM) and Initiates Humanization Process
8. R7128 Demonstrates Safety and Potent Antiviral Activity in HCV-Infected Patients
9. Rochester Medical Anti-Infection Foley Catheter Demonstrates Effectiveness in Randomized Trial
10. New Study Demonstrates 4 Year Olds Fed Enfamil LIPIL(R) as Infants Have Brain and Eye Outcomes Similar to Breastfed Babies
11. ACTOS(R) (pioglitazone HCl) Demonstrates Reduced Risk of Ischemic Cardiovascular Disease in Patients with Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... May 21, 2013  IsoRay, Inc. (AMEX: ... has entered into an exclusive international distribution agreement with ... line in Greece . IsoRay is ... and medical radioisotope applications for brain cancer, lung cancer, ... cancer. IASIS Medical is ideally suited ...
(Date:5/21/2013)... Hurel Corporation ("Hurel"), a world-leading provider of ... today announced the appointment of James S. ... of Directors. Dr. MacDonald is the former Executive Vice ... ("SPRI"), which was the pharmaceutical development arm of Schering ... in 2009. Over a career that has ...
(Date:5/21/2013)... BioElectronics Corp. (PINKSHEETS: BIEL), the maker ... that CEO, Andrew J. Whelan ... Advisory Committee, Orthopedic and Rehabilitation Panel compelling arguments ... counter sales. "It,s been 37 years ... schema," Whelan said.  "While the old classification of ...
Breaking Medicine Technology:IsoRay Announces A New International Distributor For Greece 2IsoRay Announces A New International Distributor For Greece 3Hurel Corporation Appoints Leading Pharmaceutical Executive and Toxicologist Dr. James S. MacDonald to Board of Directors 2BioElectronics Presents FDA Reclassification Panel 2BioElectronics Presents FDA Reclassification Panel 3
... N.J., Oct. 12 PharmaNet Development Group, Inc., ... innovative pharmaceutical, biotechnology, generic drug and medical device ... subsidiaries Anapharm and Taylor Technology will be showcasing ... AAPS Annual Meeting and Exposition. , Taylor ...
... Schering-Plough Corporation (NYSE: SGP ) is scheduled to ... quarter on Thursday, Oct. 22, 2009. , At ... a conference call to review results for the 2009 third ... members of management will host the conference call. , ...
Cached Medicine Technology:PharmaNet Development Group To Showcase Innovative Solutions and Poster Presentations at AAPS 2009 2PharmaNet Development Group To Showcase Innovative Solutions and Poster Presentations at AAPS 2009 3PharmaNet Development Group To Showcase Innovative Solutions and Poster Presentations at AAPS 2009 4Schering-Plough Schedules Conference Call Webcast For 2009 Third Quarter Earnings 2
(Date:5/21/2013)... Dallas, Texas (PRWEB) May 21, 2013 ... growth. Its expanding national presence has required the hiring ... , HealthSmart is pleased to announce that Dawn ... She is serving as the Director of Account Management ... HealthSmart Corporate offices in Irving, Texas. With extensive client ...
(Date:5/21/2013)... According to a May 13, 2013 New ... Botox,” Botox injections have become the most popular ... (Go to goo.gl/8iYbD). Although it is mostly associated with women, ... injection makes facial wrinkles less visible by paralyzing facial muscles. ... three months. This means that people who are conscious about ...
(Date:5/21/2013)... May 21, 2013 Global Proving Ground ... Bodybuilding.com, the largest online retailer of health and fitness ... reality-based sports show, Warrior Island. “We cast the ... Facebook & Twitter, with our unique social networking platform,” ... these elite fighters on an island in the Pacific ...
(Date:5/21/2013)... genetic features of pulmonary fibrosis by physicians and scientists ... lead to improved treatment of this deadly lung disease, ... . , The study found that a particular genetic ... fibrosis, a chronic progressive disease with a median survival ... researchers may want to consider including genetic testing in ...
(Date:5/21/2013)... May 21, 2013 The Las Vegas personal ... to announce that Crawford Gates, a senior at Coronado High ... college scholarship essay contest . As the winner of the ... essay contest started on Dec. 1, 2012 and ran through ... to submit a three-page minimum essay on “The Role of ...
Breaking Medicine News(10 mins):Health News:New Talent Joins the HealthSmart Account Management Team 2Health News:Botox – Is the World’s Most Popular Cosmetic Procedure Safe? 2Health News:Bodybuilding.com Partners with Global Proving Ground’s New Reality Show Warrior Island 2Health News:Bodybuilding.com Partners with Global Proving Ground’s New Reality Show Warrior Island 3Health News:Researchers find genetic tie to improved survival time for pulmonary fibrosis 2Health News:Benson, Bertoldo, Baker & Carter is Pleased to Announce the Winner of its First Annual College Scholarship Essay Contest 2
... 21 Talk About Curing Autism (TACA) is ... grant from the Newport Beach based Pacific Life Foundation. ... TACA will launch three new programs for Orange County, ... an in house advocate to provide education, training and ...
... Attorneys for The American Legion Department of Indiana have ... study cited by the Indiana State Department of Health ... the Indiana Soldiers, and Sailors, Children,s Home at Knightstown, ... Indiana,s Public Records Act, which requires the Department to ...
... linked to wind pattern that controls winter in Northern Hemisphere ... that flower buds are popping open earlier in the spring, ... , Not only have average worldwide temperatures been rising for ... year has shifted almost two days earlier. , That,s ...
... Jan. 21, 2009 Joslin Diabetes Center scientists are ... 2 diabetes to a new level with the launch of ... drug used for years to manage arthritis pain, can reduce ... successful, the trial could lead one day to an inexpensive ...
... ProvidersDALLAS, Jan. 21 Claimsnet.com (OTC ... MedAvant Healthcare Solutions (MedAvant) to provide a private ... MedAvant, we will be able to help our ... flow--a must in today,s market of tightening margins," ...
... popularity, it is critical for physicians to understand potential risks ... Company, the largest national insurer of physician and surgeon medical ... physicians successfully navigate telemedicine liability risks. , ... ...
Cached Medicine News:Health News:Talk About Curing Autism Receives $300,000 Grant From Pacific Life Foundation to Provide Services for Families Affected by Autism in Orange County 2Health News:Legion Attorneys Seek Copy of Health Department Study on Children's Home 2Health News:Seasons Arriving 2 Days Earlier, Study Says 2Health News:Joslin launches national study to explore if anti-inflammatory drug can treat type 2 diabetes 2Health News:Joslin launches national study to explore if anti-inflammatory drug can treat type 2 diabetes 3Health News:MedAvant and Claimsnet Form Strategic Partnership 2Health News:The Doctors Company Provides Tips for Physicians to Minimize Risk While Practicing Medicine by Phone or E-mail 2Health News:The Doctors Company Provides Tips for Physicians to Minimize Risk While Practicing Medicine by Phone or E-mail 3Health News:The Doctors Company Provides Tips for Physicians to Minimize Risk While Practicing Medicine by Phone or E-mail 4
... provides a high light intensity. ... 5 different brightness steps (Halogen ... Light output can be adapted ... cavity, small diameter scope, etc.). ...
The 300W effective dual light source has quality xenon performance....
Cold light source single outlet....
Cold light source single outlet....
Medicine Products: